Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Questions and answers about the management of Crohn’s disease and ulcerative c...
Journal Information
Vol. 42. Issue 10.
Pages 650-656 (December 2019)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 42. Issue 10.
Pages 650-656 (December 2019)
Special article
DOI: 10.1016/j.gastre.2019.08.003
Questions and answers about the management of Crohn’s disease and ulcerative colitis with vedolizumab
Preguntas y respuestas sobre el manejo de la enfermedad de Crohn y la colitis ulcerosa con vedolizumab
Visits
...
Joaquín Hinojosa del Vala,
Corresponding author
jhinojosad@gmail.com

Corresponding author.
, Manuel Barreiro-de Acostab
a Unidad de EII, Hospital de Manises, Universidad Católica de Valencia, Valencia, Spain
b Unidad de EII, Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

Vedolizumab is an anti-integrin monoclonal antibody indicated for the treatment of patients with moderately to severely active Crohn’s disease and ulcerative colitis who have failed conventional or anti-TNF therapies. The objective of this article is to answer a series of very practical questions regarding the management of both diseases with vedolizumab, based on data from published literature, as well as on the experience acquired by the authors in clinical practice in recent years.

Keywords:
Vedolizumab
Crohn’s disease
Ulcerative colitis
Management
Clinical practice
Resumen

Vedolizumab es un anticuerpo monoclonal anti-integrina indicado para el tratamiento de pacientes con enfermedad de Crohn y colitis ulcerosa moderada a grave, tras fracaso a terapia convencional o a anti-TNFs. El objetivo del presente artículo es dar respuesta a una serie de preguntas eminentemente prácticas respecto al manejo de ambas enfermedades con vedolizumab, tanto a través de evidencia clínica publicada, como de la experiencia adquirida por los autores en la práctica clínica a lo largo de los últimos años.

Palabras clave:
Vedolizumab
Enfermedad de Crohn
Colitis ulcerosa
Manejo
Práctica clínica

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.